NCT02683395终止1 期
A Phase 1b/2a, Two-Part, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Hematological Malignancies and Solid Tumors
Plexxikon5 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 50
- 试验地点
- 5
- 主要终点
- Area under the concentration-time curve (AUC) of PLX51107.
研究概览
简要总结
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced hematological malignancies
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of a relapsed or refractory malignancy in 1 of 2 treatment groups:
- •Group A: Subjects with any solid tumor (including lymphomas).
- •Group B: Subjects with relapsed or refractory AML, Subjects with relapsed or refractory high-risk MDS, defined as revised International Prognostic Scoring System (IPSS-R) intermediate or greater disease.
- •Age ≥18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 to
- •Life expectancy ≥3 months in the judgment of the investigator.
- •Adequate organ function.
- •Group A subjects must have measurable or evaluable disease per the appropriate disease criteria.
- •Women of child-bearing potential must have a negative serum pregnancy test at Screening and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.
- •Fertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug.
- •All associated clinically significant toxicity from previous cancer therapy must be resolved (to ≤Grade 1 or baseline) prior to study treatment administration (Grade 2 alopecia is allowed).
- •Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements.
排除标准
- •Prior exposure to a bromodomain inhibitor, such as OTX-015 or CPI-
- •Allogenic or autologous transplant for hematological malignancy with infusion of stem cells within 90 days before Cycle 1 Day 1, or on active immunosuppressive therapy for graft-versus-host disease (GVHD) or GVHD prophylaxis within 2 weeks of Cycle 1 Day
- •Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade
- •Uncontrolled autoimmune hemolytic anemia or thrombocytopenia.
- •For Group A: Subjects with a history of brain metastases are ineligible. This includes previously treated brain metastases. For Group B (subjects with AML): Active symptomatic CNS involvement of AML. Subjects with previously treated leptomeningeal disease that has been effectively treated are eligible.
- •A diagnosis of acute promyelocytic leukemia (APL) or chronic myeloid leukemia (CML) in blast crisis.
- •Known or suspected allergy to the investigational agent or any agent given in association with this trial.
- •Women who are pregnant or are breast feeding.
- •Clinically significant cardiac disease
- •Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption.
- •Subject with known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or is known to be a carrier of hepatitis B or C.
- •Strong CYP3A4 and CYP2C8 inhibitors or inducers or CYP3A4 substrate drugs with a narrow therapeutic range taken within 14 days or 5 drug half-lives before start of study drug.
- •Active secondary malignancy
- •Major surgery or significant traumatic injury within 14 days prior to therapy
- •Receipt of anti-cancer therapy 14 days prior to Cycle 1 Day 1
- •Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol Subjects who are participating in any other therapeutic clinical study (observational or registry trials are allowed).
- •Subjects who have Burkitt's lymphoma or Burkitt-like lymphoma.
- •Subjects on active anticoagulation therapy including warfarin, factor Xa inhibitors, thrombin inhibitors, or heparin.
- •Subjects with documented hepatic metastases involving >50% of the hepatic parenchyma.
研究组 & 干预措施
Treatment Group A
Experimental
Open label, sequential PLX51107 dose escalation in approximately 30 solid tumor subjects.
干预措施: PLX51107 (Drug)
Treatment Group B
Experimental
Open label, sequential PLX51107 dose escalation in approximately 30 subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
干预措施: PLX51107 (Drug)
结局指标
主要结局
Area under the concentration-time curve (AUC) of PLX51107.
时间窗: 1 year
Half life (t1/2) of PLX51107.
时间窗: 1 year
Time to peak concentration (Tmax) of PLX51107.
时间窗: 1 year
Safety of PLX51107 as measured by adverse events and serious adverse events.
时间窗: 1 year
Maximum observed concentration (Cmax) of PLX51107.
时间窗: 1 year
次要结局
- Overall Response Rate (ORR)(1 year)
- Duration Of Response (DOR).(1 year)
- Progression-Free Survival (PFS).(1 year)
- Overall Survival (OS).(1 year)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerPlatinum-resistant Ovarian CancerOvarian CancerFallopian Tube CancerPrimary Peritoneal CarcinomaNCT05198804K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc117
进行中（未招募）
1 期
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Lymphoma, B-CellSmall Lymphocytic LymphomaWaldenstrom MacroglobulinemiaDiffuse Large B Cell LymphomaRichter's TransformationMarginal Zone LymphomaChronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaNCT03162536ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)190
已完成
2 期
Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesThrombotic MicroangiopathiesNCT02222545Omeros Corporation58
终止
1 期
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesB-cell MalignanciesNCT02457598Gilead Sciences203
招募中
1 期
Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1Muscular Dystrophy, FacioscapulohumeralNCT06131983Sarepta Therapeutics, Inc.60